Advanced glycation end products induce proliferation, invasion and epithelial‑mesenchymal transition of human SW480 colon cancer cells through the PI3K/AKT signaling pathway

Liang,Huasheng

doi:10.3892/ol.2020.11413

Advanced glycation end products induce proliferation, invasion and epithelial‑mesenchymal transition of human SW480 colon cancer cells through the PI3K/AKT signaling pathway

Authors:
- Huasheng Liang
View Affiliations

Affiliations: Institute of Endocrine and Metabolic Diseases, Beihai People's Hospital, Beihai, Guangxi Zhuang Autonomous Region 536000, P.R. China
Published online on: February 19, 2020 https://doi.org/10.3892/ol.2020.11413
Pages: 3215-3222
Copyright: © Liang . This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to determine the mechanism by which advanced glycation end products (AGEs) induce proliferation, invasion and epithelial‑mesenchymal transition (EMT) of human colon cancer SW480 cells. SW480 cells were divided into groups as follows: i) Control; ii) cells treated with AGEs alone; and iii) cells treated with AGEs combined with LY294002. Proliferation, cell cycle progression, apoptosis, invasion and migration of SW480 cells were assessed using an MTT assay, flow cytometry, Transwell assays and a wound healing assay, respectively. The protein expression levels of PI3K, AKT and epithelial cadherin (E‑cadherin) were examined by western blot analysis in SW480 cells treated with various concentrations of AGEs. Proliferation, invasion and migration were enhanced, cell cycle progression was increased and apoptosis was decreased in SW480 cells treated with AGEs compared with the control. The PI3K inhibitor, LY294002, reversed the effects of AGEs. Western blot analysis data demonstrated that AGEs increased the protein expression levels of PI3K and AKT, and decreased the expression of E‑cadherin. The results suggested that AGEs exert a positive effect on the proliferation, invasion and EMT in SW480 cells through the PI3K/AKT signaling pathway.

View Figures

View References

1	Cao H, Xu E, Liu H, Wan L and Lai M: Epithelial-mesenchymal transition in colorectal cancer metastasis: A system review. Pathol Res Pract. 211:557–569. 2015. View Article : Google Scholar : PubMed/NCBI
2	Kang KA, Piao MJ, Ryu YS, Hyun YJ, Park JE, Shilnikova K, Zhen AX, Kang HK, Koh YS, Jeong YJ and Hyun JW: Luteolin induces apoptotic cell death via antioxidant activity in human colon cancer cells. Int J Oncol. 51:1169–1178. 2017. View Article : Google Scholar : PubMed/NCBI
3	Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI
4	Brownlee M: Advanced protein glycosylation in diabetes and aging. Annu Rev Med. 46:223–234. 1995. View Article : Google Scholar : PubMed/NCBI
5	Hori O, Yan SD, Ogawa S, Kuwabara K, Matsumoto M, Stern D and Schmidt AM: The receptor for advanced glycation end-products has a central role in mediating the effects of advanced glycation end-products on the development of vascular disease in diabetes mellitus. Nephrol Dial Transplant. 11 (Suppl 5):S13–S16. 1996. View Article : Google Scholar
6	Schmidt AM, Yan SD, Wautier JL and Stern D: Activation of receptor for advanced glycation end products: A mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. Circ Res. 84:489–497. 1999. View Article : Google Scholar : PubMed/NCBI
7	Bao JM, He MY, Liu YW, Lu YJ, Hong YQ, Luo HH, Ren ZL, Zhao SC and Jiang Y: AGE/RAGE/Akt pathway contributes to prostate cancer cell proliferation by promoting Rb phosphorylation and degradation. Am J Cancer Res. 5:1741–1750. 2015.PubMed/NCBI
8	Lee KJ, Yoo JW, Kim YK, Choi JH, Ha TY and Gil M: Advanced glycation end products promote triple negative breast cancer cells via ERK and NF-κB pathway. Biochem Biophys Res Commun. 495:2195–2201. 2018. View Article : Google Scholar : PubMed/NCBI
9	Neviere R, Yu Y, Wang L, Tessier F and Boulanger E: Implication of advanced glycation end products (Ages) and their receptor (Rage) on myocardial contractile and mitochondrial functions. Glycoconj J. 33:607–617. 2016. View Article : Google Scholar : PubMed/NCBI
10	Sun L, Huang T, Xu W, Sun J, Lv Y and Wang Y: Advanced glycation end products promote VEGF expression and thus choroidal neovascularization via Cyr61-PI3K/AKT signaling pathway. Sci Rep. 7:149252017. View Article : Google Scholar : PubMed/NCBI
11	Nasser MW, Wani NA, Ahirwar DK, Powell CA, Ravi J, Elbaz M, Zhao H, Padilla L, Zhang X, Shilo K, et al: RAGE mediates S100A7-induced breast cancer growth and metastasis by modulating the tumor microenvironment. Cancer Res. 75:974–985. 2015. View Article : Google Scholar : PubMed/NCBI
12	Qin Q, Niu J, Wang Z, Xu W, Qiao Z and Gu Y: Heparanase induced by advanced glycation end products (AGEs) promotes macrophage migration involving RAGE and PI3K/AKT pathway. Cardiovasc Diabetol. 12:372013. View Article : Google Scholar : PubMed/NCBI
13	Li G, Xu J and Li Z: Receptor for advanced glycation end products inhibits proliferation in osteoblast through suppression of Wnt, PI3K and ERK signaling. Biochem Biophys Res Commun. 423:684–689. 2012. View Article : Google Scholar : PubMed/NCBI
14	Thiery JP: Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer. 2:442–454. 2002. View Article : Google Scholar : PubMed/NCBI
15	Karin M, Yamamoto Y and Wang QM: The IKK NF-kB system: A treasure trove for drug development. Nat Rev Drug Discov. 3:17–26. 2004. View Article : Google Scholar : PubMed/NCBI
16	Downward J: Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer. 3:11–22. 2003. View Article : Google Scholar : PubMed/NCBI
17	Huber MA, Kraut N and Beug H: Molecular requirements for epithelial-mesenchymal transition during tumor progression. Curr Opin Cell Biol. 17:548–558. 2005. View Article : Google Scholar : PubMed/NCBI
18	Shimomoto T, Luo Y, Ohmori H, Chihara Y, Fujii K, Sasahira T, Denda A and Kuniyasu H: Advanced glycation end products (AGE) induce the receptor for AGE in the colonic mucosa of azoxymethane-injected Fischer 344 rats fed with a high-linoleic acid and high-glucose diet. J Gastroenterol. 47:1073–1083. 2012. View Article : Google Scholar : PubMed/NCBI
19	Chen H, Wu L, Li Y, Meng J, Lin N, Yang D, Zhu Y, Li X, Li M, Xu Y, et al: Advanced glycation end products increase carbohydrate responsive element binding protein expression and promote cancer cell proliferation. Mol Cell Endocrinol. 395:69–78. 2015. View Article : Google Scholar
20	Grote VA, Nieters A, Kaaks R, Tjønneland A, Roswall N, Overvad K, Nielsen MR, Clavel-Chapelon F, Boutron-Ruault MC, Racine A, et al: The associations of advanced glycation end products and its soluble receptor with pancreatic cancer risk: A case-control study within the prospective EPIC cohort. Cancer Epidemiol Biomarkers Prev. 21:619–628. 2012. View Article : Google Scholar : PubMed/NCBI
21	Takino J, Yamagishi S and Takeuchi M: Glycer-AGEs-RAGE signaling enhances the angiogenic potential of hepatocellular carcinoma by upregulating VEGF expression. World J Gastroenterol. 18:1781–1788. 2012. View Article : Google Scholar : PubMed/NCBI
22	Ishibashi Y, Matsui T, Takeuchi M and Yamagishi S: Metformin inhibits advanced glycation end products (AGEs)-induced growth and VEGF expression in MCF-7 breast cancer cells by suppressing AGEs receptor expression via AMP-activated protein kinase. Horm Metab Res. 45:387–390. 2013.PubMed/NCBI
23	Chen H, Li Y, Zhu Y, Wu L, Meng J, Lin N, Yang D, Li M, Ding W, Tong X and Su Q: Advanced glycation end products promote ChREBP expression and cell proliferation in liver cancer cells by increasing reactive oxygen species. Medicine (Baltimore). 96:e74562017. View Article : Google Scholar : PubMed/NCBI
24	Liu X, Liu K, Wang Z, Liu C, Han Z, Tao J, Lu P, Wang J, Wu B, Huang Z, et al: Advanced glycation end products accelerate arteriosclerosis after renal transplantation through the AGE/RAGE/ILK pathway. Exp Mol Pathol. 99:312–319. 2015. View Article : Google Scholar : PubMed/NCBI
25	Foster D, Spruill L, Walter KR, Nogueira LM, Fedarovich H, Turner RY, Ahmed M, Salley JD, Ford ME, Findlay VJ and Turner DP: AGE metabolites: A biomarker linked to cancer disparity? Cancer Epidemiol Biomarkers Prev. 23:2186–2191. 2014. View Article : Google Scholar : PubMed/NCBI
26	Vlassara H and Uribarri J: Advanced glycation end products (AGE) and diabetes: Cause, effect, or both? Curr Diab Rep. 14:4532014. View Article : Google Scholar : PubMed/NCBI
27	Duan Z, Chen G, Chen L, Stolzenberg-Solomon R, Weinstein SJ, Mannisto S, White DL, Albanes D and Jiao L: Determinants of concentrations of N(ε)-carboxymethyl-lysine and soluble receptor for advanced glycation end products and their associations with risk of pancreatic cancer. Int J Mol Epidemiol Genet. 5:152–163. 2014.PubMed/NCBI
28	Yang S, Pinney SM, Mallick P, Ho SM, Bracken B and Wu T: Impact of oxidative stress biomarkers and carboxymethyllysine (an advanced glycation end product) on prostate cancer: A prospective study. Clin Genitourin Cancer. 13:e347–e351. 2015. View Article : Google Scholar : PubMed/NCBI
29	Nicholson KM and Anderson NG: The protein kinase B/Akt signalling pathway in human malignancy. Cell Signal. 14:381–395. 2002. View Article : Google Scholar : PubMed/NCBI
30	Xin M and Deng X: Nicotine inactivation of the proapoptotic function of Bax through phosphorylation. J Biol Chem. 280:10781–10789. 2005. View Article : Google Scholar : PubMed/NCBI
31	Semba S, Itoh N, Ito M, Harada M and Yamakawa M: The in vitro and in vivo effects of 2-(4-morpholinyl)-8-phenyl-chromone (LY294002), a specific inhibitor of phosphatidylinositol 3′-kinase, in human colon cancer cells. Clin Cancer Res. 8:1957–1963. 2002.PubMed/NCBI
32	Hu L, Zaloudek C, Mills GB, Gray J and Jaffe RB: In vivo and in vitro ovarian carcinoma growth inhibition by a phosphatidylinositol 3-kinase inhibitor (LY294002). Clin Cancer Res. 6:880–886. 2000.PubMed/NCBI
33	Song G, Ouyang G and Bao S: The activation of Akt/PKB signaling pathway and cell survival. J Cell Mol Med. 9:59–71. 2005. View Article : Google Scholar : PubMed/NCBI
34	Zheng J, Koh X, Hua F, Li G, Larrick JW and Bian JS: Cardioprotection induced by Na+/K+-ATPase activation involves extracellular signal-regulated kinase 1/2 and phosphoinositide 3-kinase/Akt pathway. Cardiovasc Res. 89:51–59. 2011. View Article : Google Scholar : PubMed/NCBI
35	Liu Q, Turner KM, Alfred Yung WK, Chen K and Zhang W: Role of AKT signaling in DNA repair and clinical response to cancer therapy. Neuro Oncol. 16:1313–1323. 2014. View Article : Google Scholar : PubMed/NCBI
36	Blume-Jensen P and Hunter T: Oncogenic kinase signalling. Nature. 411:355–365. 2001. View Article : Google Scholar : PubMed/NCBI
37	Boudot C, Saidak Z, Boulanouar AK, Petit L, Gouilleux F, Massy Z, Brazier M, Mentaverri R and Kamel S: Implication of the calcium sensing receptor and the Phosphoinositide 3-kinase/Akt pathway in the extracellular calcium-mediated migration of RAW 264.7 osteoclast precursor cells. Bone. 46:1416–1423. 2010. View Article : Google Scholar : PubMed/NCBI
38	Granado MH, Gangoiti P, Ouro A, Arana L, González M, Trueba M and Gómez-Muñoz A: Ceramide 1-phosphate (C1P) promotes cell migration: Involvement of a specific C1P receptor. Cell Signal. 21:405–412. 2009. View Article : Google Scholar : PubMed/NCBI
39	Wallesch M, Pachow D, Blücher C, Firsching R, Warnke JP, Braunsdorf WEK, Kirches E and Mawrin C: Altered expression of E-Cadherin-related transcription factors indicates partial epithelial-mesenchymal transition in aggressive meningiomas. J Neurol Sci. 380:112–121. 2017. View Article : Google Scholar : PubMed/NCBI
40	Prieto-García E, Díaz-García CV, García-Ruiz I and Agulló-Ortuño MT: Epithelial-to-mesenchymal transition in tumor progression. Med Oncol. 34:1222017. View Article : Google Scholar : PubMed/NCBI
41	Huber MA, Azoitei N, Baumann B, Grünert S, Sommer A, Pehamberger H, Kraut N, Beug H and Wirth T: NF-кB is essential for epithelial-mesenchymal transition and metastasis in a model of breast cancer progression. J Clin Invest. 114:569–581. 2004. View Article : Google Scholar : PubMed/NCBI